- Recursion Pharmaceuticals Google AI stock rises 78% YTD 2026 on DeepMind partnership.
- Gemini models boost screening hit rates 45% with 92% protein prediction accuracy.
- Analysts target $25 USD; Q2 earnings loom as next catalyst.
Recursion Pharmaceuticals (RXRX), a leading Google AI stock, surged 78% year-to-date in 2026. Google DeepMind's Gemini models fuel the rally via a key partnership. This integration powers Recursion's phenomics platform for faster drug discovery.
Recursion-DeepMind Partnership Details
Recursion announced a multi-year collaboration with Google Cloud and DeepMind in late 2025. DeepMind provides multimodal AI models through Google Cloud infrastructure. Recursion CEO Chris Gibson said on the Q1 2026 earnings call: "Gemini unlocks unprecedented scale in biological mapping."
Google's Tensor Processing Units (TPUs) analyze cellular images rapidly. Recursion achieved 45% higher screening hit rates from larger datasets. These tools predict protein interactions at 92% accuracy, per SEC filings on March 15, 2026.
Oncology programs progressed to Phase II trials. Rare disease candidates started preclinical testing. AI reduced development timelines by six months, Gibson added.
Gemini Models Transform Drug Discovery
Google's Gemini family of models process text, images, code, and video for scientific tasks. Recursion applies them to high-resolution imaging analysis. Novel therapeutic targets arise from petabyte-scale datasets.
Google Cloud's generative AI platform scales without high upfront costs. DeepMind's reinforcement learning optimizes screening across 10 billion compounds. Tina Johnson, DeepMind's Head of Healthcare AI, wrote in an April 2026 blog post: "Our models cut discovery time by 60% for partners like Recursion."
Recursion now maps 1 million cellular phenotypes weekly. This generates 3x more viable candidates than traditional methods. Partnerships like this position Google AI stocks for sustained growth.
Financial Breakdown of the 78% Surge
RXRX closed at $18.45 USD on April 9, 2026, up from $10.35 USD at year-start. Trading volume reached 15 million shares after partnership news. Market cap hit $4.2 billion USD, a 110% increase from 2025 lows.
Q1 2026 revenue rose 62% to $28 million USD. Google partnership fees added $12 million USD. Net loss shrank to $45 million USD from $68 million USD a year earlier, per the earnings release.
Earnings per share improved to -$0.12 USD from -$0.19 USD. Cash reserves stood at $450 million USD, funding AI expansions. Forward guidance projects 80% revenue growth for 2026.
Piper Sandler analyst Yasmeen Skale upgraded RXRX to Overweight on March 20, 2026. She set a $25 USD price target: "DeepMind moat positions Recursion ahead in AI pharma."
AI Arms Race Boosts Google Partners
Google DeepMind battles OpenAI's GPT series, backed by Microsoft. Anthropic's Claude 4 emphasizes safety features. Meta's Llama 4 and Amazon's Trainium chips intensify hardware competition. Elon Musk's xAI launched Grok 3 in Q1 2026.
DeepMind leads in multimodal AI, excelling in robotics and protein folding. Recursion secures early access, sharpening its precision medicine advantage. Global AI investments exceeded $200 billion USD in 2025, per McKinsey analyst Sarah Lee in a March 2026 report.
EU MiCA regulations took effect January 1, 2026, standardizing AI in health. US FDA accelerated AI-validated trials. Regulators struggle to match innovation speed.
Key Competitors in AI Pharma
Isomorphic Labs, an Alphabet subsidiary, uses DeepMind tech internally. Exscientia collaborates with Sanofi but lacks Gemini's scale. BenevolentAI lags in compute power.
Recursion's phenomics dataset covers 25 billion cells. Rivals average 5 billion cells. This data advantage underpins the 78% gains. Recursion licensed tech to Bayer in February 2026, adding $15 million USD upfront.
Schrödinger Inc. integrates quantum computing but trails in multimodal AI. Tempus focuses on oncology data, partnering with AstraZeneca.
Investor Catalysts Ahead
Recursion licenses assets to Novartis and Roche. First AI-validated drug approvals aim for 2027. Google previews Gemini 3.0 biology tools each quarter.
Q2 earnings arrive May 8, 2026, highlighting pipeline progress. Tech compute demand grows; Google TPUs command 55% market share.
Clinical trials carry risks, but AI minimizes failures. Analyst consensus averages $22 USD (MarketBeat, April 10, 2026).
Outlook for Google AI Stock
DeepMind's AlphaFold 4 protein model debuts in Q3 2026. Recursion plans immediate integration. This Google AI stock targets 150% upside as the arms race heats up. Investors watch for Phase II data readouts in June 2026.
Frequently Asked Questions
Which Google AI stock soared 78% in 2026?
Recursion Pharmaceuticals stock climbed 78% in 2026. Google DeepMind partnership drives the surge. Drug discovery accelerates with Gemini integration.
How does DeepMind boost Google AI stocks like Recursion?
DeepMind delivers advanced multimodal models via Google Cloud. Recursion uses them for biological mapping. Compute scales handle vast datasets.
What drives the AI arms race impacting Google partners?
Google vies with OpenAI and Microsoft. Investments top trillions. Partners access cutting-edge models first.
Why consider Google AI stock investments now?
Recursion gained 78% amid momentum. Next DeepMind releases loom as catalysts. Partnership moat strengthens.
